Huang X, Yu Y, Luo S, Fu W, et al. The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on >/= 1 line of endocrine therapy: systematic review and meta-analysis. BMC Cancer 2024;24:21.
PMID: 38166684